en
svPress releases
Regulatory press release 2021-04-08
Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA)
Regulatory press release 2021-03-19
Xspray Pharma publishes its annual report for 2020
Press release 2021-03-18
Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021
Press release 2021-03-05
Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed
Regulatory press release 2021-02-25
Xspray Pharma publishes Interim report Q4, January – December 2020
Regulatory press release 2021-02-17
Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma
Regulatory press release 2021-01-29
Number of shares and votes in Xspray Pharma
Regulatory press release 2021-01-26
Warrant holders exercise all warrants within the framework of the incentive program
Regulatory press release 2021-01-22
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started
Regulatory press release 2021-01-14